Oxford Square Capital Corp. (OXSQ) is a Greenwich, Connecticut-based business development company (BDC) — a publicly traded firm that lends to and invests in smaller businesses and passes most of its income to shareholders. Oxford Square focuses on syndicated bank loans and, to a lesser extent, debt and equity tranches of collateralized loan obligation (CLO) vehicles. After a sharp year-long decline, the shares now trade far below the company's own reported book value, raising a direct question: can they climb back toward $1.20?
Oxford Square has effectively no meaningful analyst consensus. A single verifiable target from a named firm — Lucid Capital Markets' Hold rating with a $1.75 price target, initiated October 1, 2025 by analyst Erik Zwick — is now well above the current price and predates much of the subsequent decline. A separate estimate of about $1.15 appears on some quote pages but cannot be tied to specific, current analyst reports. With fewer than two credible, current targets, a consensus-based figure is not reliable here.
Instead, the $1.20 objective rests on a valuation argument that is widely discussed for BDCs: the gap between share price and book value. Oxford Square's NAV per share was $1.21 on September 30, 2026, yet the stock trades near $0.81 — a discount of roughly 33%. A re-rating toward NAV, even partially, is the natural objective embedded in this fallback target. It is a public, valuation-anchored reference point, not a published analyst consensus.
The shares recently traded around $0.81, giving the company a market capitalization near $98 million. Reaching $1.20 would require an advance of about 48%, a very large move that would still leave the stock only at its book value rather than a premium. The 52-week range spans roughly $0.78 to $2.01, underscoring how far the shares have fallen.
The path toward the target would most plausibly run through stabilization of NAV and a re-rating of the discount, rather than through rapid earnings growth. In the quarter ended September 30, 2026, Oxford Square reported net investment income of about $4.9 million, or $0.04 per share, on total investment income near $9.9 million, while combined realized and unrealized losses of roughly $3.3 million continued to pressure book value. Any sustained recovery would likely need credit losses to moderate, distributions to stabilize, and the market to once again price the shares closer to their underlying assets.
Oxford Square sits near the bottom of its 52-week range, with the $0.78 area acting as the most relevant support level — the prior 52-week low. On the upside, the stock remains below all major long-term moving averages, and the former trading zone well above $1.00 now represents overhead resistance. The $1.20 target itself aligns closely with book value, a level the market last supported before the NAV decline accelerated. For a BDC, the psychological anchor is less a round number than the gap between price and NAV.
Analyst price targets typically reflect a research horizon of roughly 12 months, though Oxford Square's single dated target cannot anchor a reliable time frame. Investors should watch quarterly NAV disclosures, the trajectory of net investment income relative to the reduced distribution, credit-loss trends, further share issuance or buyback activity, and interest-rate policy, which affects both floating-rate loan income and the financing costs of CLO structures.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single forecast, the system scans for changing trends so traders can discover opportunities, monitor existing positions, and spot momentum shifts more efficiently. For investors following Oxford Square Capital and comparable names, the AI Daily Buy/Sell Signals offer a way to track evolving conditions without manually reviewing every chart.
The question of whether Oxford Square Capital (OXSQ) can reach $1.20 is ultimately a question of whether its deep discount to book value can narrow. The target is a valuation-based reference point tied to a NAV of $1.21 per share, not an analyst consensus, and it requires a gain of roughly 48% from recent levels near $0.81. The strongest supports are the discount itself, an income-oriented yield, and a floating-rate loan portfolio, while the principal obstacles are the distribution cut, continuing NAV erosion, credit losses, and dilution. With essentially one stale analyst target and a rapidly changing balance sheet, investors have no reliable consensus to lean on. Monitoring NAV trends, distribution sustainability, and share-count changes will be central to assessing whether a move toward book value is realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OXSQ has been loosely correlated with NEWT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if OXSQ jumps, then NEWT could also see price increases.
| Ticker / NAME | Correlation To OXSQ | 1D Price Change % | ||
|---|---|---|---|---|
| OXSQ | 100% | -1.31% | ||
| NEWT - OXSQ | 43% Loosely correlated | -0.55% | ||
| MSDL - OXSQ | 32% Poorly correlated | -0.43% | ||
| TRIN - OXSQ | 29% Poorly correlated | N/A | ||
| HRZN - OXSQ | 28% Poorly correlated | +0.66% | ||
| BCSF - OXSQ | 27% Poorly correlated | +0.36% | ||
More | ||||